Search

Your search keyword '"Yan, Lun-Jie"' showing total 147 results
Start Over Author "Yan, Lun-Jie"
147 results on '"Yan, Lun-Jie"'

4. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients

Author

Han, Cheng-Long, Tian, Bao-Wen, Yan, Lun-Jie, Ding, Zi-Niu, Liu, Hui, Mao, Xin-Cheng, Tian, Jin-Cheng, Xue, Jun-Shuai, Tan, Si-Yu, Dong, Zhao-Ru, Yan, Yu-Chuan, Hong, Jian-Guo, Chen, Zhi-Qiang, Wang, Dong-Xu, and Li, Tao

Published
2023
Full Text
View/download PDF

17. Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis

Author

Cao, Qi‐Hang, primary, Liu, Hui, additional, Yan, Lun‐Jie, additional, Wang, Han‐Chao, additional, Ding, Zi‐Niu, additional, Mao, Xin‐Cheng, additional, Li, Rui‐Zhe, additional, Pan, Guo‐Qiang, additional, Zhang, Xiao, additional, Tian, Bao‐Wen, additional, Han, Cheng‐Long, additional, Dong, Zhao‐Ru, additional, Tan, Si‐Yu, additional, Wang, Dong‐Xu, additional, Yan, Yu‐Chuan, additional, and Li, Tao, additional

Published
2024
Full Text
View/download PDF

18. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Author

Han, Cheng-Long, primary, Tian, Bao-Wen, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Liu, Hui, additional, Pan, Guo-Qiang, additional, Zhang, Xiao, additional, Mao, Xin-Chen, additional, Tan, Si-Yu, additional, Li, Rui-Zhe, additional, Wang, Dong-Xu, additional, Dong, Zhao-Ru, additional, Yan, Yu-Chuan, additional, and Li, Tao, additional

Published
2024
Full Text
View/download PDF

20. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis

Author

Li, Han, primary, Liu, Hui, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Zhang, Xiao, additional, Pan, Guo-Qiang, additional, Han, Cheng-Long, additional, Tian, Bao-Wen, additional, Tan, Si-Yu, additional, Dong, Zhao-Ru, additional, Wang, Dong-Xu, additional, Yan, Yu-Chuan, additional, and Li, Tao, additional

Published
2023
Full Text
View/download PDF

21. CTNNB1-mutation-related immune gene prognostic model (CMRIPM) for hepatocellular carcinoma: Development and validation

Author

Li, Rui-Zhe, primary, Ding, Zi-Niu, additional, Meng, Guang-Xiao, additional, Liu, Hui, additional, Xue, Jun-Shuai, additional, Yan, Lun-Jie, additional, Dong, Zhao-Ru, additional, Hong, Jian-Guo, additional, Chen, Zhi-Qiang, additional, Tian, Bao-Wen, additional, Han, Cheng-Long, additional, Wang, Dong-Xu, additional, and Li, Tao, additional

Published
2023
Full Text
View/download PDF

23. RET mutation as a putative prognostic biomarker for immune checkpoint inhibitors therapy in various malignancies

Author

Long, Jun-Yu, primary, Li, Rui-Zhe, additional, Wang, Dong-Xu, additional, Liu, Hui, additional, Tian, Jincheng, additional, Ding, Zi-Niu, additional, Yan, Lun-Jie, additional, Dong, Zhao-Ru, additional, Hong, Jian-Guo, additional, Tian, Bao-Wen, additional, Han, Cheng-Long, additional, Zhao, Hai-Tao, additional, and Li, Tao, additional

Published
2023
Full Text
View/download PDF

24. Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis

Author

Liu, Hui, primary, Yang, Chun-Cheng, additional, Ma, Yun-Long, additional, Yang, Ya-Fei, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Xue, Jun-Shuai, additional, Yang, Long-Shan, additional, Yan, Yu-Chuan, additional, Dong, Zhao-Ru, additional, Wang, Dong-Xu, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, and Li, Tao, additional

Published
2023
Full Text
View/download PDF

26. A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response

Author

Ma, Yun-Long, primary, Yang, Ya-Fei, additional, Wang, Han-Chao, additional, Yang, Chun-Cheng, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Tian, Bao-Wen, additional, Liu, Hui, additional, Xue, Jun-Shuai, additional, Han, Cheng-Long, additional, Tan, Si-Yu, additional, Hong, Jian-Guo, additional, Yan, Yu-Chuan, additional, Mao, Xin-Cheng, additional, Wang, Dong-Xu, additional, and Li, Tao, additional

Published
2023
Full Text
View/download PDF

27. Comprehensive Molecular Analysis Identifies Ret Alterations Association with Response of Icis in Multi-Immunotherapy Cohorts

Author

Long, Junyu, primary, Li, Rui-Zhe, additional, Wang, Dong-Xu, additional, Liu, Hui, additional, Tian, Jincheng, additional, Ding, Zi-Niu, additional, Yan, Lun-Jie, additional, Dong, Zhao-Ru, additional, Hong, Jian-Guo, additional, Tian, Bao-Wen, additional, Han, Cheng-Long, additional, Li, Tao, additional, and Zhao, Haitao, additional

Published
2023
Full Text
View/download PDF

30. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis

Author

Tian, Bao-Wen, primary, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Liu, Hui, additional, Meng, Guang-Xiao, additional, Xue, Jun-Shuai, additional, Han, Cheng-Long, additional, Dong, Zhao-Ru, additional, Hong, Jian-Guo, additional, Chen, Zhi-Qiang, additional, Wang, Dong-Xu, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

31. Systemic immune–inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis

Author

Tian, Bao-Wen, primary, Yang, Ya-Fei, additional, Yang, Chun-Cheng, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Liu, Hui, additional, Xue, Jun-Shuai, additional, Dong, Zhao-Ru, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, Wang, Dong-Xu, additional, Han, Cheng-Long, additional, Mao, Xin-Cheng, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

33. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis

Author

Tian, Jin-Cheng, primary, Liu, Hui, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Han, Cheng-Long, additional, Tian, Bao-Wen, additional, Tan, Si-Yu, additional, Dong, Zhao-Ru, additional, Wang, Dong-Xu, additional, Xue, Jun-Shuai, additional, Mao, Xin-Cheng, additional, Yan, Yu-Chuan, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

36. The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Author

Xue, Jun-Shuai, primary, Ding, Zi-Niu, additional, Meng, Guang-Xiao, additional, Yan, Lun-Jie, additional, Liu, Hui, additional, Li, Hai-Chao, additional, Yao, Sheng-Yu, additional, Tian, Bao-Wen, additional, Dong, Zhao-Ru, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, Wang, Dong-Xu, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

37. The Association of Glycemic Index, Glycemic Load, and Daily Carbohydrates Intake with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Author

Yang, Long-Shan, Yan, Lun-Jie, Meng, Guang-Xiao, Ding, Zi-Niu, Yao, Sheng-Yu, Li, Hai-Chao, Dong, Zhao-Ru, Chen, Zhi-Qiang, Hong, Jian-Guo, and Li, Tao

Subjects
*ONLINE information services, *META-analysis, *MEDICAL information storage & retrieval systems, *CONFIDENCE intervals, *FOOD consumption, *SYSTEMATIC reviews, *CARBOHYDRATE content of food, *CASE-control method, *HEPATITIS viruses, *GLYCEMIC index, *RISK assessment, *CARBOHYDRATES, *RESEARCH funding, *MEDLINE, *ODDS ratio, *HEPATOCELLULAR carcinoma, *LONGITUDINAL method, *DISEASE risk factors
Abstract

Background: Glycemic index (GI), glycemic load (GL) and daily carbohydrates intake have been associated with a variety of cancers, but their implications in hepatocellular carcinoma (HCC) remain controversial. The purpose of our study is to investigate the association of GI, GL and daily carbohydrates intake with the risk of HCC. Methods: Systematic searches were conducted in PubMed, Embase and Web of Science until November 2020. According to the degree of heterogeneity, random effect model or fixed effect model was chosen to obtain the pooled relative risks (RRs) and corresponding 95% confidence intervals (CIs). Results: Four cohort studies and three case-control studies were eventually included. The pooled results showed no significant association of GI (RR = 1.11, 95% CI = 0.80-1.53), GL (RR = 1.09, 95% CI = 0.76-1.55), and daily carbohydrates intake (RR = 1.09, 95% CI = 0.84-1.32) with the risk of HCC in the general population. Subgroup analysis revealed that in hepatitis B virus (HBV) or/and hepatitis C virus (HCV)-positive group, GI was irrelevant to the risk of HCC (RR = 0.65, 95% CI = 0.32-1.32), while a high GL diet was associated with a higher risk of HCC (RR = 1.52, 95% CI = 1.04-2.23). In contrast, in HBV and HCV-negative group, both GI (RR = 1.23, 95% CI = 0.88-1.70) and GL (RR = 1.17, 95% CI = 0.83-1.64) were not associated with the risk of HCC. Conclusion: A high GL diet increases the risk of HCC in those with viral hepatitis. A low GL diet is recommended for them to reduce the risk of HCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis.

Author

Han, Cheng-Long, Tian, Bao-Wen, Yang, Chun-Cheng, Yang, Ya-Fei, Ma, Yun-Long, Ding, Zi-Niu, Yan, Lun-Jie, Liu, Hui, Dong, Zhao-Ru, Chen, Zhi-Qiang, Hong, Jian-Guo, Wang, Dong-Xu, and Li, Tao

Subjects
HEPATOCELLULAR carcinoma, HEPATITIS B virus, UNIVARIATE analysis, MULTIVARIATE analysis, HEPATITIS C, FATTY liver
Abstract

Fatty liver (FL) is reportedly a risk factor for hepatocellular carcinoma (HCC) in individuals affected with Hepatitis C (HCV) or B (HBV) virus. However, the results are contradictory, necessitating a meta-analysis. Sixteen relevant studies involving 88,618 individuals were retrieved from the Cochrane Library, PubMed, MEDLINE, Embase, and Scopus databases from their inception to 10 December 2022. The hazard ratios (HR) and 95% confidence intervals (CI) were analyzed. Liver biopsy-proven FL may be a significant risk factor for HCC in individuals affected with HBV (univariate analyses: HR = 3.13, 95% CI = 1.69–5.79; multivariate analyses: HR = 3.42, 95% CI = 0.83–14.09) as well as HCV (univariate analyses: HR = 1.64, 95% CI = 0.93–2.90; multivariate analyses: HR = 1.75, 95% CI = 1.02–3.00). However, the presence of FL confirmed using reasonable methods other than liver biopsy may not indicate a risk for HCC in HBV-infected individuals (univariate analyses: HR = 0.90, 95% CI = 0.44–1.81; multivariate analyses: HR = 0.69, 95% CI = 0.45–1.08). Biopsy-proven FL may be a significant risk factor for HCC in HCV/HBV-infected individuals. Thus, such individuals should receive suitable interventions to prevent HCC formation or at least attenuate the risk of HCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.

Author

Tian, Bao-Wen, Yan, Lun-Jie, Ding, Zi-Niu, Liu, Hui, Meng, Guang-Xiao, Xue, Jun-Shuai, Han, Cheng-Long, Dong, Zhao-Ru, Hong, Jian-Guo, Chen, Zhi-Qiang, Wang, Dong-Xu, and Li, Tao

Subjects
ALPHA fetoproteins, IMMUNE checkpoint inhibitors, HEPATOCELLULAR carcinoma, SURVIVAL rate, OVERALL survival, PROGNOSIS
Abstract

The prognostic value of alpha-fetoprotein (AFP) response for efficacy of targeted therapy or immune checkpoint inhibitors (ICIs) has not been established. The purpose of this meta-analysis is to elucidate the relationship between AFP response and survival outcomes in hepatocellular carcinoma (HCC) patients who received targeted therapy or ICIs. The hazard ratio (HR) with 95% confidence interval (CI) was used to evaluate the relationship between AFP response and overall survival (OS)/progression-free survival (PFS). Twenty-six articles containing 3056 HCC patients were finally included in the study. The pooled results showed that after targeted therapy or ICIs, patients with decrease in AFP had better prognosis (OS:HR = 0.48, 95%CI:0.40–0.56; PFS:HR = 0.39, 95%CI:0.33–0.46), while patients with increase in AFP had worse prognosis (OS:HR = 2.30, 95%CI:1.82–2.89; PFS:HR = 2.34, 95%CI = 1.69–3.24). Subgroup analysis revealed that compared to AFP decrease >50%, AFP decrease >20% can better predict the prognosis of patients who received targeted therapy (OS:HR = 0.51, 95%CI:0.41–0.62; PFS:HR = 0.39, 95%CI:0.30–0.51) or ICIs treatment (OS:HR = 0.34, 95%CI:0.16–0.71; PFS:HR = 0.22, 95%CI:0.10–0.47), and 8 weeks after targeted therapy may be the appropriate time point for AFP assessment. AFP decrease >20% within 8 weeks may be the appropriate definition for early AFP response which probably works best in predicting the efficacy of therapy. The review was not registered. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

Author

Han, Cheng-Long, primary, Meng, Guang-Xiao, additional, Ding, Zi-Niu, additional, Dong, Zhao-Ru, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, Yan, Lun-Jie, additional, Liu, Hui, additional, Tian, Bao-Wen, additional, Yang, Long-Shan, additional, Xue, Jun-Shuai, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

44. Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies

Author

Yan, Yu-Chuan, primary, Meng, Guang-Xiao, additional, Ding, Zi-Niu, additional, Liu, Yan-Feng, additional, Chen, Zhi-Qiang, additional, Yan, Lun-Jie, additional, yang, Ya-Fei, additional, Liu, Hui, additional, Yang, Chun-Cheng, additional, Dong, Zhao-Ru, additional, Hong, Jian-Guo, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

46. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis

Author

Xue, Jun-shuai, primary, Liu, Hui, additional, Meng, Guang-Xiao, additional, Ding, Zi-Niu, additional, Yan, Lun-Jie, additional, Yao, Sheng-Yu, additional, Li, Hai-Chao, additional, Dong, Zhao-Ru, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, and Li, Tao, additional

Published
2021
Full Text
View/download PDF

48. Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis

Author

Liu, Kai-Xuan, primary, Hong, Jian-Guo, additional, Wu, Rui, additional, Dong, Zhao-Ru, additional, Yang, Ya-Fei, additional, Yan, Yu-Chuan, additional, Yang, Chun-Cheng, additional, Yan, Lun-Jie, additional, Yao, Sheng-Yu, additional, Li, Hai-Chao, additional, Zhi, Xu-Ting, additional, and Li, Tao, additional

Published
2021
Full Text
View/download PDF

49. Effects of hypoxia‐inducible factor‐1α and hypoxia‐inducible factor‐2α overexpression on hepatocellular carcinoma survival: A systematic review with meta‐analysis

Author

Ding, Zi‐Niu, primary, Dong, Zhao‐Ru, additional, Chen, Zhi‐Qiang, additional, Yang, Ya‐Fei, additional, Yan, Lun‐Jie, additional, Li, Hai‐Chao, additional, Liu, Kai‐Xuan, additional, Yao, Cheng‐Yu, additional, Yan, Yu‐Chuan, additional, Yang, Chun‐Cheng, additional, and Li, Tao, additional

Published
2021
Full Text
View/download PDF

50. Gender Differences and Regional Disparities of Incidence of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Systematic Review and Meta-Analysis

Author

Yan, Lun-Jie, primary, Yao, Sheng-Yu, additional, Meng, Guang-Xiao, additional, Liu, Kai-Xuan, additional, Dong, Zhao-Ru, additional, Hong, Jian-Guo, additional, Li, Hai-Chao, additional, Yang, Ya-Fei, additional, Yan, Yu-Chuang, additional, Ding, Zi-Niu, additional, and Li, Tao, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results